BMS & Receptos v. Synthon: Ozanimod Patent Suit Dismissed Without Prejudice
Bristol-Myers Squibb and Receptos LLC filed suit in Delaware against Dutch generics maker Synthon B.V. over US11680050B2, a patent covering ozanimod tablets — the active ingredient in Zeposia. After 440 days of litigation, both parties stipulated to dismiss all claims without prejudice, with each side bearing its own costs.
Ozanimod generic battle shelved — but door left open
On 2 July 2024, Bristol-Myers Squibb Company and its subsidiary Receptos LLC filed a patent infringement action in the District of Delaware against Synthon B.V., a Netherlands-based generic pharmaceutical manufacturer. The complaint asserted US11680050B2 — a patent covering ozanimod tablet formulations at the 0.23 mg, 0.46 mg, and 0.92 mg doses marketed under the brand name Zeposia for relapsing multiple sclerosis and ulcerative colitis. The suit followed Synthon’s filing of an Abbreviated New Drug Application (ANDA) seeking to commercialise generic ozanimod tablets.
After 440 days, the parties jointly stipulated to dismiss all claims, counterclaims, defenses, motions, and petitions without prejudice on 15 September 2025. The court retained jurisdiction solely for the purpose of enforcing the stipulation. Critically, the dismissal was expressly characterised as ‘not an adjudication on the merits,’ and each party waived any right to appeal or move for relief from the order. Each side bears its own litigation costs and attorneys’ fees, with no damages or injunctive relief awarded.
A without-prejudice dismissal after 440 days — without a merits ruling — suggests the parties likely reached a private commercial resolution, possibly a patent licence or settlement agreement with supply timing provisions, though none has been publicly disclosed. The absence of a merits adjudication means US11680050B2 remains unchallenged through this litigation and continues to be presumptively valid. What remains unknown from the public record is whether Synthon received a negotiated launch date, a royalty-bearing licence, or simply agreed to delay its ANDA. IP professionals tracking the ozanimod exclusivity landscape should monitor any subsequent ANDA filings or licensing disclosures.
Filing to Dismissed without Prejudice in 440 days
440 days — longer than the median ANDA Hatch-Waxman first-instance case in Delaware
Dismissed without prejudice: what the stipulation means for both parties
Stipulated dismissal without prejudice — no merits ruling
A dismissal ‘without prejudice’ means no court has ruled on whether US11680050B2 is valid, infringed, or enforceable. The parties jointly filed a stipulation that formally ends this litigation instance but explicitly preserves the right to refile. The court retained jurisdiction only to enforce the stipulation itself, not to resolve any substantive patent dispute.
No adjudication on the meritsThe prejudice distinction matters — the public record is silent on terms
A ‘without prejudice’ dismissal differs critically from a ‘with prejudice’ one: BMS and Receptos retain the right to refile patent claims against Synthon based on the same patent. This structure is consistent with a private settlement that may include a negotiated launch date or licence — but no such agreement appears in the public docket. The public record does not disclose any settlement terms, and this content does not assert any.
Refiling right preservedSynthon avoids an adverse ruling — but US11680050B2 stands unchallenged
Synthon escapes this litigation without a finding of infringement or an injunction. However, the patent at suit was never invalidated or found unenforceable — meaning Synthon’s ANDA path remains commercially uncertain. Future market entry would still require a licence, regulatory clearance, or a fresh challenge to the patent’s validity, potentially via IPR at the USPTO.
No invalidity ruling obtainedOzanimod exclusivity landscape remains intact for BMS
Because the dismissal carries no merits adjudication, US11680050B2 emerges from this case legally unscathed and presumptively valid. Generic entry for ozanimod tablets remains contingent on either a future challenge or a private arrangement. Competitors and payers tracking the Zeposia exclusivity cliff should note that this resolution does not signal imminent generic availability in the absence of a disclosed licence.
Patent exclusivity preservedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Bristol-Myers Squibb | Individual | Pharmaceutical innovator — holder of US11680050B2 covering ozanimod formulationsSearch in Eureka ↗ |
| Co-Plaintiff | Receptos LLC | Company | Search in Eureka ↗ |
| Defendant | Synthon, BV | Individual | Dutch generic drug manufacturer; ANDA filer for ozanimod tablets 0.23–0.92 mgSearch in Eureka ↗ |
| Plaintiff counsel | Akkad Y. Moussa | Attorney | Counsel for Bristol-Myers SquibbSearch in Eureka ↗ |
| Plaintiff counsel | Amy K. Wigmore | Attorney | Counsel for Bristol-Myers SquibbSearch in Eureka ↗ |
| Plaintiff counsel | Gerard A. Salvatore | Attorney | Counsel for Bristol-Myers SquibbSearch in Eureka ↗ |
| Plaintiff counsel | Heather M. Petruzzi | Attorney | Counsel for Bristol-Myers SquibbSearch in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Bristol-Myers SquibbSearch in Eureka ↗ |
| Plaintiff counsel | Jeremy A. Tigan | Attorney | Counsel for Bristol-Myers SquibbSearch in Eureka ↗ |
| Plaintiff counsel | Joshua L. Stern | Attorney | Counsel for Bristol-Myers SquibbSearch in Eureka ↗ |
| Plaintiff counsel | Li-tsung A. Chen | Attorney | Counsel for Bristol-Myers SquibbSearch in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Bristol-Myers SquibbSearch in Eureka ↗ |
| Defendant counsel | Catherine Lynch | Attorney | Counsel for Synthon, BVSearch in Eureka ↗ |
| Defendant counsel | Jennifer Nock | Attorney | Counsel for Synthon, BVSearch in Eureka ↗ |
| Defendant counsel | Melanie K. Sharp | Attorney | Counsel for Synthon, BVSearch in Eureka ↗ |
| Defendant counsel | Stephanie Vangellow | Attorney | Counsel for Synthon, BVSearch in Eureka ↗ |
| Defendant law firm | Young Conaway Stargatt & Taylor, LLP | Law Firm | Representing Synthon, BVSearch in Eureka ↗ |
| Presiding judge | Judge Gregory B. Williams | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation’s express language — ‘not an adjudication on the merits’ — is legally significant: it forecloses any argument that this dismissal constitutes issue preclusion or res judicata on questions of infringement, validity, or enforceability of US11680050B2. Both parties’ waiver of appellate rights confirms this is a final resolution of this particular action, not a procedural pause. The each-party-bears-own-costs allocation is commercially neutral but is consistent with a negotiated outcome rather than a litigant conceding defeat.
US11680050B2 — Ozanimod tablet formulations (Zeposia)
US11680050B2, filed under application number US16/748303, covers ozanimod tablet formulations — including the dose strengths of 0.23 mg, 0.46 mg, and 0.92 mg commercially available as Zeposia. Ozanimod is a sphingosine 1-phosphate (S1P) receptor modulator approved for relapsing forms of multiple sclerosis and moderately-to-severely active ulcerative colitis. The patent represents downstream formulation IP layered on top of the core ozanimod chemistry, and its scope is central to the Zeposia commercial exclusivity strategy.
From a competitive standpoint, US11680050B2 functions as a key barrier to generic entry for the Zeposia franchise. Receptos LLC — acquired by Bristol-Myers Squibb — is the assignee and the suit demonstrates that BMS is prepared to actively enforce this IP against ANDA applicants. For pharmaceutical manufacturers and investors, the patent’s survival in this litigation (without any validity challenge resolved on the merits) signals continued commercial risk for any generic ozanimod programme targeting the US market before the patent’s expiry.
Should you run an FTO analysis against US11680050B2?
Any pharmaceutical company or CDMO considering development, formulation, or commercialisation of generic ozanimod tablets in the US market should treat US11680050B2 as an active FTO risk. BMS has demonstrated willingness to enforce this patent in Delaware — the leading forum for Hatch-Waxman litigation. The patent was not invalidated in this action, and no public licence terms exist that would provide third-party cover. R&D teams working on S1P receptor modulator generics should prioritise FTO clearance before ANDA submission.
PatSnap Eureka’s FTO Search Agent allows IP and R&D teams to map the full ozanimod patent landscape, identify claim scope of US11680050B2, surface related BMS and Receptos portfolio patents, and flag any pending applications that may extend exclusivity. Eureka’s AI-assisted analysis can benchmark your formulation against claim language and generate a structured FTO report — enabling faster, evidence-based decisions on development risk before committing resources to an ANDA programme.
Run a freedom-to-operate analysis on US11680050B2 to assess your product’s exposure
Run FTO in Eureka →Similar ozanimod and S1P modulator patent cases in Delaware
Explore related Hatch-Waxman ANDA patent infringement cases involving ozanimod and S1P receptor modulators litigated in the District of Delaware.
What this case signals for the pharmaceutical ANDA IP landscape
Without-prejudice exits in Hatch-Waxman cases rarely signal pure surrender — they typically indicate a private deal that public filings cannot confirm.
Without-prejudice dismissals frequently mask confidential licensing deals
In Hatch-Waxman litigation, a stipulated without-prejudice dismissal after extended proceedings is a well-recognised signal of a private settlement — often involving a negotiated authorised generic arrangement or a defined entry date. IP teams monitoring ozanimod should watch for any FDA ANDA approval or supply agreement disclosures from Synthon.
US11680050B2 is unchallenged — FTO risk persists for ANDA filers
No court has ruled on the validity or enforceability of US11680050B2. Any generic manufacturer targeting the ozanimod market must independently assess this patent through their own FTO analysis or consider an IPR petition at the USPTO. The absence of an invalidity ruling in this case provides no cover for third-party ANDA applicants.
Squibb v Synthon — key questions answered
The case was dismissed without prejudice by joint stipulation on 15 September 2025 after 440 days of litigation. No merits ruling was issued on infringement, validity, or enforceability of US11680050B2. Each party agreed to bear its own costs and attorneys’ fees, and both waived any right to appeal the stipulation.
Plaintiffs asserted US11680050B2 (application number US16/748303), covering ozanimod tablet formulations at 0.23 mg, 0.46 mg, and 0.92 mg dose strengths — the doses marketed as Zeposia. The patent is assigned to Receptos LLC and relates to pharmaceutical formulation claims for the S1P receptor modulator ozanimod.
Not necessarily. A dismissal without prejudice means BMS and Receptos retain the right to refile patent claims against Synthon. US11680050B2 was not invalidated or found unenforceable. Synthon’s ability to launch generic ozanimod in the US still depends on regulatory approval, patent expiry, or a separate licensing arrangement — none of which are confirmed by the public record in this case.
The case was filed in the United States District Court for the District of Delaware and was presided over by Judge Gregory B. Williams. Delaware is the primary venue for Hatch-Waxman ANDA patent litigation, and Morris, Nichols, Arsht & Tunnell LLP represented the plaintiffs, while Young Conaway Stargatt & Taylor, LLP represented Synthon.
The express ‘not an adjudication on the merits’ language in the stipulation means the dismissal cannot be used as issue preclusion or res judicata in any future litigation between these parties or against third parties. US11680050B2 remains presumptively valid. BMS and Receptos are legally free to refile against Synthon or assert the same patent against other ANDA filers without prejudice from this case’s resolution.
PatSnap Eureka searches patents and litigation data to answer instantly.